ORJEMSA
Dead / Abandoned — Abandoned — no statement of use filed (as of 17 Feb 2025)
What this means for you
This application is over — abandoned 17 Feb 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97591746
- Mark type
- Stylized text
- Filed
- 14 Sept 2022
- Published for opposition
- 21 May 2024
- Abandoned
- 17 Feb 2025
- Attorney of record
- Connie L. Ellerbach
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders; targeted pharmaceutical preparations for use in cancer prevention and treatment; pharmaceutical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders
- Class 044 — Medical, beauty and agricultural services: Medical information services; healthcare services; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; medical information services, namely, providing information regarding viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders
Owner
- Day One Biopharmaceuticals, Inc., Brisbane, CA, US
- Day One Biopharmaceuticals, Inc., Brisbane, CA, US
Prosecution history
- 17 Feb 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 17 Feb 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 10 Jan 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 10 Jan 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 10 Jan 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 16 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 21 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 May 2024 — PUBLISHED FOR OPPOSITION
- 01 May 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Apr 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Apr 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 Apr 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Apr 2024 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 02 Jan 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 02 Jan 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED